PEGylation has been successfully applied in various therapeutics, including PEGylated liposomes for drug and siRNA delivery. Numerous studies have demonstrated that PEGylation can increase the ...

Q1 2024 Earnings Call Transcript May 2, 2024 NovoCure Limited beats earnings expectations. Reported EPS is $-0.36134, ...

Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first ...

H ealth Canada has granted approval to Nora Pharma for the commercialisation of its first biosimilar product, Niopeg (a ...

NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching ...

End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in ...

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio (INMB – Research Report), with a ...

A Chiesi survey has found widespread unmet needs among Fabry disease patients taking drugs such as Sanofi’s Fabrazyme, ...

Currently, it is unknown whether planned sequential delivery of active agents (for example, carboplatin for three to four cycles followed by three cycles of pegylated liposomal doxorubicin ...

Currently, for patients with dominant HCV infection and low level HBV viremia (<10 4 IU/mL), IFN or pegylated IFN plus ribavirin can achieve comparable sustained virus response as expected with ...

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune ...

RVR Undetectable HCV-RNA at week 4 of treatment by a sensitive, qualitative or quantitative HCV-RNA assay EVR ≥2 log reduction of HCV-RNA at week 12 of treatment compared to baseline level by a ...